Cause Of Coronary Heart Disease Research Articles

Antioxidant potential of diet – Association between dietary antioxidant index and odds of coronary heart disease: A case-control study

BACKGROUND: Oxidative stress and chronic inflammation are among the leading causes of coronary heart disease (CHD). Studies investigated the relationship between dietary antioxidants and the risk/odds of CHD, and contradictory results have been reported. Dietary antioxidant index (DAI) is a novel and reliable nutritional tool that examines the diet’s overall antioxidant capacity. Its validity was examined using serum total antioxidant capacity and malondialdehyde. OBJECTIVE: This study aimed to investigate the relationship between DAI score and odds of CHD. METHODS: In this incidence case-control study, 320 individuals with a definitive diagnosis of CHD and 320 participants without CHD or related risk factors attending the same hospitals/polyclinics were selected as the case and control groups. We estimated the DAI by summing up six standardized intakes of major dietary antioxidants, including manganese, vitamin E, A, C, selenium, and zinc. RESULTS: Modeling DAI categorized according to the median (–0.38), in multi-adjusted model showed a significant protective association with the odd of CHD (OR = 0.72; 95%CI:0.51–0.99, p-value = 0.05). Also, modeling DAI as a continuous variable in multi-adjusted models (OR = 0.94;95%CI:0.90–0.95; p-value = 0.01) showed significant results. CONCLUSION: Using the DAI to investigate the relationship between dietary antioxidants and CHD can show more realistic results than a single study of antioxidants.

Circular RNA circCHFR downregulation protects against oxidized low-density lipoprotein-induced endothelial injury via regulation of microRNA-15b-5p/growth arrest and DNA damage inducible gamma

ABSTRACT Atherosclerosis is the leading cause of coronary heart disease. In recent years, circ_0029589 (circCHFR) has been found to be associated with atherosclerosis development. However, the molecular mechanism of circCHFR action in atherosclerosis development is unknown. This study was aimed to investigate the function and action mechanism of circCHFR in atherosclerosis development. An atherosclerosis cell model was created by exposing human vascular endothelial cells (HUVECs) to oxidized low-density lipoprotein. The expression of circCHFR, microRNA(miR)-15b-5p, growth arrest and DNA damage inducible gamma (GADD45G), and their associated proteins was evaluated using quantitative reverse transcription-polymerase chain reaction and Western blotting. Additionally, cell viability, apoptosis, and cytokine levels were determined using Cell Counting Kit-8 (CCK8) assay, flow cytometry, and enzyme-linked immunosorbent assay, respectively. circCHFR expression was upregulated in patients with atherosclerosis and oxidized low-density lipoprotein (ox-LDL)-exposed HUVECs, whereas miR-15b-5p expression was downregulated. circCHFR silencing significantly improved viability and reduced apoptosis of HUVECs. In addition, the pro-apoptotic protein Bax and atherosclerosis-associated cytokines (interleukin-1β, interleukin-6, and tumor necrosis factor-α) were significantly downregulated, whereas the anti-apoptotic protein Bcl-2 was upregulated. Further, we discovered that circCHFR serves as a molecular sponge of miR-15b-5p. GADD45G was found to be an important target of miR-15b-5p; miR-15b-5p mimic inhibited GADD45G expression, reduced apoptosis and proinflammatory cytokine secretion, and improved cell survival. However, these effects of miR-15b-5p on (ox-LDL) induced HUVECs were reversed with GADD45G plasmid co-transfection. In conclusion, circCHFR promotes atherosclerosis progression via the miR-15b-5p/GADD45G axis and may be an important target for atherosclerosis treatment.

Abstract PO-010: Increased risk of smoking-related health conditions for current and former smokers in the Chicago metro area

Abstract PURPOSE: Smoking is a main cause of lung cancer and COPD and is also a cause of coronary heart disease, stroke and a host of other cancers and diseases. The purpose of this study was to investigate rates of smoking-related health conditions in the Chicago metro area and to assess how cigarette use and demographic factors correlate with increased risk for these conditions. METHODS: The Behavioral Risk Factor Surveillance System (BRFSS) is a national system of health-related telephone surveys that collect state data about U.S. residents regarding their health-related risk behaviors, chronic health conditions, and use of preventive services. A subsample of the 2019 BRFSS data from the Chicago metro-area was used (n=4,838). Analysis was conducted with STATA survey analysis tools to account for the complex sampling design of BRFSS data. Logistic regression models predicting increased risk for each health condition for 3 categories of smokers (current, quit in past 10 years, quit >10 years ago) compared to non-smokers and including age, sex, race, income, and BMI as covariates were run. RESULTS: Rates of health problems of Chicago area residents were: 5.9% non-skin cancer, 5.1% COPD, 8.4% asthma, 5.0% coronary heart disease/myocardial infarction (MI/CHD), 2.8% stroke, 30.2% hypertension, 10.4% diabetes, and 7.5% poor/fair health. Current smoking was associated with increased odds of COPD (7.3 [4.7, 11.4]), asthma (1.8 [1.2, 2.6]), hypertension (1.6 [1.2, 2.1]), diabetes (1.5 [1.0, 2.3]), and poor/fair health (1.8 [1.3, 2.5]). Those that quit smoking in the past 10 years had increased odds of COPD (2.9 [1.7, 5.1]), stroke (2.6 [1.3, 5.4]), diabetes (1.9 [1.2, 2.9]), and poor/fair health (1.5 [1.1, 2.2]). Those that quit more than 10 years ago had increased odds of non-skin cancer (1.6 [1.1, 2.3]), COPD (2.3 [1.5, 3.6]), and MI/CHD (2.2 [1.4, 3.2]). Demographic factors also predicted greater risk of smoking-related health conditions after controlling for smoking status including greater risk for Black residents of stroke (2.0 (1.1, 3.7)], hypertension (1.7 [1.3, 2.2]), diabetes (1.7 [1.2, 2.4]), and poor/fair health (1.7 [1.3, 2.4]) and increased risk for Hispanic residents of diabetes (2.4 [1.6, 3.4]) and poor/fair health (2.5 [1.8, 3.3]). Lower income predicted greater risk for MI/CHD (1.9 [1.3, 2.9]), stroke (2.2 [1.2, 4.2]), hypertension (1.5 [1.2, 1.9]), diabetes (1.5 [1.1, 2.1]) and poor/fair health (3.0 [2.3, 3.8]). CONCLUSION: Risks for smoking-related health conditions varied for current and former cigarette users and also by different demographic factors for Chicago metro-area residents. These findings can inform clinical work by revealing the continued health risks even for those who quit smoking and how risks my be exacerbated for different racial groups and for those with lower income. Citation Format: Larisa A. Burke, Alana D. Steffen, Cherdsak Duangchan, Karriem S. Watson, Alicia K. Matthews. Increased risk of smoking-related health conditions for current and former smokers in the Chicago metro area [abstract]. In: Proceedings of the AACR Virtual Conference: 14th AACR Conference on the Science of Cancer Health Disparities in Racial/Ethnic Minorities and the Medically Underserved; 2021 Oct 6-8. Philadelphia (PA): AACR; Cancer Epidemiol Biomarkers Prev 2022;31(1 Suppl):Abstract nr PO-010.

On improving the Quality Of Life of the Elderly -- Analysis on the Prevention and Health Education of Common Diseases of the Elderly

With the advent of the aging process, the quality of life of the elderly has become one of the important topics in aging research. In the outbreak of novel coronavirus pneumonia in 2020, more than 60% of the infected people were middle-aged and elderly. Therefore, the quality of life of the elderly, especially the health of the body, was once again highly concerned. This paper expounds the common diseases of the elderly, such as urinary tract infection, the causes of coronary heart disease, common symptoms, health education and symptomatic treatment, so as to strive to prevent the disease before the disease, prevent the disease from changing, further promote their health and improve their quality of life.

Abstract 10863: Genome-Wide Assessments of 138 Inflammatory Markers Identified Inflammatory Pathways Confer Cardiovascular Disease Risk

Introduction: Atherosclerosis, the main underlying causes of coronary heart disease (CHD) and ischemic stroke, is an inflammatory condition. However, therapeutics targeting inflammation for CHD and stroke are limited, partially due to insufficient evidence for causal inflammatory pathways and druggable targets. Objectives: We aimed to identify causal inflammatory markers for CHD and ischemic stroke, and to characterize the genetic architecture shared between such an inflammatory profile and CHD/stroke. Methods: Pooling multiple databases, we curated the largest genome-wide association summary statistics for 138 markers including 126 inflammatory proteins (C-reactive protein [CRP], N>450k; others such as cytokines, N~3.6k-45k) and 12 blood immune cell types (N>450k) and subsets (N~2.5k); as well as for CHD (N~547k) and stroke (N~521k). We conducted Mendelian randomization (MR) analysis using Causal Analysis Using Summary Effect Estimates and Mode-Based Estimate; and the genome-wide cross-trait meta-analysis using Association analysis based on SubSETs. Results: Of the 138 inflammatory markers, MR analyses identified 3 cellular and 4 protein markers showing significant causal effects for CHD (including white blood cell count, CD8+ T count, interleukin 6, and interleukin 22 receptor subunit alpha 1; FDR <0.05); and 4 protein markers showing significant causal effects for ischemic stroke (including interleukin 6 and macrophage migration inhibitory factor; FDR <0.05). Genome-wide cross-trait analysis identified 456 independent genetic loci that significantly co-regulated cardiovascular disease (CHD or stroke) and at least one of its causal inflammatory markers (e.g., APOC1-4 coregulated CHD and 5 causal markers for CHD; lead SNPs showing P <5e-8 in each pair of marker-disease meta-analysis and FDR <0.01 with each trait). In tissue-specific gene expression analysis, the expressions of genes harboring these loci showed a significant enrichment in blood, blood vessels, and adipose tissue ( FDR <0.05), and a marginal enrichment in the liver and lung ( P <0.05). Conclusions: We identified cellular and protein inflammatory markers that potentially have a causal role in the development of CHD and ischemic stroke, based on genetic evidence.

The Potency of Bovine Bone Gelatin as Antihypertensive Agent: A Review

This review was purposed to understand the effectiveness of bovine bone gelatin as an antihypertensive agent. This review concerning the effectiveness of bovine bone gelatin as an antihypertensive agent. Hypertension, also called as a silent disease, has become the main cause of coronary heart disease and stroke that contributes to the malfunction of human organs. Changes of lifestyle alongside with science enhancement, provides new inventions regarding methods of hypertension therapy by minimizing the use of synthetic drugs. Collagen tissue of bovine bone gelatin is known to contain angiotensin converting enzyme (ACE) inhibitor, an active peptide that plays a role in lowering blood pressure supporting with the large amount of Gly (27%), Pro (17.6%), and Hyp (14.4%) and repeating pattern of Gly-X-Y. A study was carried out in vivo using injected spontaneously hypertensive rats (SHR) with 30 mg/kg and was able to reduce blood pressure by 15 mmHg. Antihypertensive test with SHR tail-cuff at 30 mg/kg bovine gelatin hydrolysate RGL-(Hyp)-GL and RGM-(Hyp)-GF were 31.3 mmHg and 38.6 mmHg respectively. A study conducted using bovine and porcine gelatin with 30–50 kDa (permeate P1) and 1–2 kDa (permeate P3) was able to reduce blood pressure by 22 mmHg and 21.33 mmHg. In addition, it is still possible conducting research to find out other peptides of bovine bone gelatin that can be used as a future alternative antihypertensive agent.

Revisiting Candidacy: What Might It Offer Cancer Prevention?

The notion of candidacy emerged three decades ago through Davison and colleagues’ exploration of people’s understanding of the causes of coronary heart disease. Candidacy was a mechanism to estimate one’s own or others risk of disease informed by their lay epidemiology. It could predict who would develop illness or explain why someone succumbed to it. Candidacy’s predictive ability, however, was fallible, and it was from this perspective that the public’s reticence to adhere to prevention messages could be explained, as ultimately anybody could be ‘at-risk’. This work continues to resonate in health research, with over 700 citations of Davison’s Candidacy paper. Less explored however, is the candidacy framework in its entirety in other illness spheres, where prevention efforts could potentially impact health outcomes. This paper revisits the candidacy framework to reconsider it use within prevention. In doing so, candidacy within coronary heart disease, suicide prevention, diabetes, and cancer will be examined, and key components of candidacy and how people negotiate their candidacy within differing disease contexts will be uncovered. The applicability of candidacy to address modifiable breast cancer risk factors or cancer prevention more broadly will be considered, as will the implications for public health policy.

ROLE OF MICRONUTRIENTS IN HEART DISEASES

Heart disease is a common occurrence in older patients in the civilized culture, and the rate is predicted to rise as the software advances. Patients with heart disease should be intended to eat a salt-free diet to lose adiposity. Diet is also critical for heart disease patients; those with nutrition deficits have a low deep prognosis. A growing body of research indicates a correlation between heart disease and a lack of micronutrients. Repairable heart disease has been linked to thiamine and selenium deficiency. Micronutrients and heart disease may, nevertheless, have a more moderate association, according to recent research. This article looks at studies that looked at micronutrient consumption, supplement effectiveness, and micronutrient ingestion in heart disease patients, with an emphasis on retinol, ascorbic acid, a fat-soluble vitamin, vitamin B1, other B vitamins, cholecalciferol, folate, iron, and copper. Because aging is the leading cause of coronary heart disease, treatments intended to reduce down the aging process or improving life expectancy are distinctly different from their standards for the treatment of coronary heart disease. Altering risky life decisions which might relate to aging and coronary heart diseases, such as nicotine usage, obesity, and unique lifestyles, is increasingly become part of the quality of practice.

Gut Microbiome, Functional Food, Atherosclerosis, and Vascular Calcifications-Is There a Missing Link?

The gut microbiome is represented by the genome of all microorganisms (symbiotic, potential pathogens, or pathogens) residing in the intestine. These ecological communities are involved in almost all metabolic diseases and cardiovascular diseases are not excluded. Atherosclerosis, with a continuously increasing incidence in recent years, is the leading cause of coronary heart disease and stroke by plaque rupture and intraplaque hemorrhage. Vascular calcification, a process very much alike with osteogenesis, is considered to be a marker of advanced atherosclerosis. New evidence, suggesting the role of dietary intake influence on the diversity of the gut microbiome in the development of vascular calcifications, is highly debated. Gut microbiota can metabolize choline, phosphatidylcholine, and L-carnitine and produce vasculotoxic metabolites, such as trimethylamine-N-oxide (TMAO), a proatherogenic metabolite. This review article aims to discuss the latest research about how probiotics and the correction of diet is impacting the gut microbiota and its metabolites in the atherosclerotic process and vascular calcification. Further studies could create the premises for interventions in the microbiome as future primary tools in the prevention of atherosclerotic plaque and vascular calcifications.

The Effects of Diosgenin on Hypolipidemia and Its Underlying Mechanism: A Review.

Hyperlipidemia is a disorder of lipid metabolism, which is a major cause of coronary heart disease. Although there has been considerable progress in hyperlipidemia treatment, morbidity and risk associated with the condition continue to rise. The first-line treatment for hyperlipidemia, statins, has multiple side effects; therefore, development of safe and effective drugs from natural products to prevent and treat hyperlipidemia is necessary. Diosgenin is primarily derived from fenugreek (Trigonella foenum graecum) seeds, and is also abundant in medicinal herbs such as Dioscorea rhizome, Dioscorea septemloba, and Rhizoma polygonati, is a well-known steroidal sapogenin and the active ingredient in many drugs to treat cardiovascular conditions. There is abundant evidence that diosgenin has potential for application in correcting lipid metabolism disorders. In this review, we evaluated the latest evidence related to diosgenin and hyperlipidemia from clinical and animal studies. Additionally, we elaborate the pharmacological mechanism underlying the activity of diosgenin in treating hyperlipidemia in detail, including its role in inhibition of intestinal absorption of lipids, regulation of cholesterol transport, promotion of cholesterol conversion into bile acid and its excretion, inhibition of endogenous lipid biosynthesis, antioxidation and lipoprotein lipase activity, and regulation of transcription factors related to lipid metabolism. This review provides a deep exploration of the pharmacological mechanisms involved in diosgenin-hyperlipidemia interactions and suggests potential routes for the development of novel drug therapies for hyperlipidemia.

EXPERIMENTAL VERIFICATION OF THE AUTHOR'S PROGRAM OF PSYCHOCORRECTION OF EMOTIONAL STATES OF ELDERLY WOMEN WITH PARTICULAR HEART DISEASE

The article presents the results of an experimental test of the author's program of psychocorrection of emotional states of elderly women with coronary heart disease. The main psychophysiological indicators of the emotional state of elderly women, which affect the development of coronary heart disease, are determined. These include: alexithymia, depression, openness, anxiety, neuroticism, sociability, emotional lability. The following methods of processing the obtained results were chosen, in view of the small number of respondents: Spearman's rank correlation method, Student's T-test; T - Wilcoxon test). Methods used: "Toronto Alexithymic Scale", "Hamilton Scale for Depression", "Hamilton Scale for Anxiety", "Asthenic Scales", "Neuropsychiatric Stress Questionnaire", "Aggression Questionnaire", "FR Questionnaire , according to theoretically determined indicators of the emotional sphere of elderly women with coronary heart disease. It was found that for psychophysiological indicators of depression, anxiety, neuroticism, openness, emotional lability, significance was recorded using Wilcoxon's T-test, which indicates that the change in these indicators occurred as a result of our method with a probability of more than 99%. It is noted that the level of psychophysiological indicators of alexithymia and sociability did not change significantly. We explain the weak influence of the proposed method on these indicators by objective factors. Correction of alexithymia should include a focus on the patient's awareness of their feelings and the ability to express them and should be carried out on the patient comprehensively and over a long period of time. We have identified an important cause of coronary heart disease in elderly women, which is a combination of elevated levels of negative emotions with an intense tendency to suppress their expression in social contacts and interpersonal interaction. The effectiveness of the correctional program has been proved, which can be further used by psychologists as a psychocorrectional component of the general set of measures during outpatient treatment of coronary heart disease and its psychoprophylaxis. We see the prospect of further research in the improvement of the author's comprehensive program, expansion of its corrective spectrum of action and further testing.

Genetic Diagnostic Approaches in Familial Hypercholesterolemia Evaluation

Abstract Familial hypercholesterolemia (FH) manifested as atherosclerosis is a major cause of coronary heart disease. Different scoring systems based on clinical and paraclinical data are currently used, but the FH diagnosis should be made only in the presence of the causative genetic defect. In the present study, 12 symptomatic (previously diagnosed with atherosclerosis) and asymptomatic family members were investigated. Serum lipids were measured using commercial reagents. A genetic investigation was performed by Sanger sequencing using commercial reagents and custom primers, while copy number variations and a selected set of 40 point mutations were evaluated using in vitro diagnostic medical devices. For the investigated patients, serum lipids were within the reference range, due to the fact that the subjects were following lipid-lowering therapy, and smoking was the only identifiable additional risk factor. Four benign exon variants and three intron variants situated within the low-density lipoprotein cholesterol receptor gene were identified by Sanger sequencing. No copy number variations and none of the 40 investigated point mutations were determined. Although independently considered benign, the combined effect of the identified genetic conditions could be pathogenic under the influence of additional risk factors. Even in the presence of a diagnosis made using clinical scores, the molecular diagnosis is often challenging, attesting to the complexity of FH genetic etiology.

Silent myocardial ischemia in patients with type 2 diabetes mellitus: a clinical case

Background. Type 2 diabetes mellitus (DM) is an important medical, social, and economic problem due to the high prevalence of the disease, which often leads to disability and significantly increases mortality in elderly people. One of the causes of coronary heart disease (CHD) in patients with type 2 DM is autonomic cardiovascular neuropathy, which is characterized by damage to the autonomic nervous system and manifests itself in a varying clinical picture, including silent myocardial ischemia (SMI). The prevalence of SMI among patients with type 2 DM is much higher than in people without it. The purpose was to study the clinical case of a patient with type 2 DM and CHD, raise awareness of the prevalence and influence of type 2 DM on CHD progression by focusing on diagnostic research and treatment strategies. Materials and methods. The clinical case of the detected silent ischemia in a patient with type 2 DM was analyzed. The complaints were as following: high blood pressure, moderate shortness of breath during walking, pain, and numbness of the lower extremities. Anamnesis: type 2 DM over 20 years; endovascular stenting of the right common iliac artery due to obliterating atherosclerosis of the arteries of the lower extremities; hypertension over 10 years; obesity. Based on this data, CHD was suspected. Results. The Holter monitoring revealed rare episodes of reversible ischemic repolarization. ECG demonstrated the deviation of the electrical axis to the left, hypertrophy of the left ventricular myocardium, diffuse violation of repolarization processes. Ultrasound of the heart found aortic atherosclerosis, left ventricular myocardial hypertrophy, a moderate decrease in myocardial contractility. Ultrasound of vessels of the lower extremities showed the signs of obliterating atherosclerosis with decompensation of peripheral blood flow. Coronary angiography demonstrated left coronary artery with critical subocclusions (90 %), right coronary artery with chronic occlusion in the middle segment (100 %). There was established the diagnosis: coronary heart disease (silent ischemia); diffuse stenotic atherosclerosis of the coronary artery (coronary angiography May 2019); arterial hypertension II stage, degree 2; HF II stage; II NYHA; type 2 diabetes mellitus, insulin-dependent, decompensated; obesity I stage; obliterating atherosclerosis of the arteries of the lower extremities (condition after endovascular stenting of the right common iliac artery on January 2018); chronic pancreatitis in remission, peptic ulcer of the duodenum (operated in 1981); chronic cholecystitis in remission. The treatment was prescribed: insulin therapy, nebivolol, eplerenone, candesartan, clopidogrel, rosuvastatin. Coronary artery bypass grafting is recommended. Conclusions. Thereby, timely diagnosis and adequate treatment can avoid complications of type 2 DM and improve quality and lifetime. With type 2 DM, CHD is often masked and remains undiagnosed, leading to complications and death, therefore more attention to such patients is needed.

MODEL EPIDEMIK SEIR PADA KASUS PENYAKIT JANTUNG KORONER PADA PENDERITA KOLESTROL

Coronary heart disease (CHD) is caused by various reasons. One of the main causes of coronary heart disease is cholesterol. Cholesterol comes from two sources, namely, that which is produced by the liver and through the food consumed. This article discusses the mathematical model of coronary heart disease which refers to the SEI (Susceptible-exposed-infected) model, with modifications in the form of the addition of the recovered (R) variable and parameters in the form of a healthy lifestyle and surgery. Hereinafter this model is called the SEIR (Susceptible-Exposed-Infected-Recovered) model. This study aims to determine the problem of coronary heart disease in cholesterol sufferers and to analyze the effect of operating parameters and a healthy lifestyle on the patient's healing (R) is higher than the opportunity value of the other groups. And the opportunity value of an infected individual is much lower than that of other groups. This shows that the chances of recovery for people with coronary heart disease with a high operating route.

Enhancer of zeste homolog 2 participates in the process of atherosclerosis by modulating microRNA-139-5p methylation and signal transducer and activator of transcription 1 expression.

Atherosclerosis (AS) is the main cause of coronary heart disease, in which enhancer of zeste homolog 2 (EZH2) has been implied to participate in this process. Thus, this work proposed to explore the effect of EZH2 on AS from microRNA-139-5p (miR-139-5p)/signal transducer and activator of transcription 1 (STAT1) axis. EZH2, miR-139-5p, and STAT1 expression in arterial tissues of AS patients were detected. Human arterial smooth muscle cells (HASMCs) induced with oxidized low-density lipoprotein (ox-LDL) and the mice fed with high fat diet were treated with silenced EZH2 or upregulated miR-139-5p to explore their roles in proliferation and apoptosis of HASMCs, together with inflammation response and oxidative stress of mice. Chromatin immunoprecipitation experiment was applied to verify the regulatory effect of EZH2 on miR-139-5p through methylation of H3K27me3. The targeting relationship between miR-139-5p and STAT1 was verified by online website and luciferase activity assay. Reduced miR-139-5p and overexpressed EHZ2 and STAT1 were found in AS. Silenced EZH2 or elevated miR-139-5p decreased the production of cholesterol and inhibited inflammation reaction in serum of mice with AS. Silenced EZH2 or elevated miR-139-5p facilitated proliferation and restrained apoptosis of ox-LDL-treated HASMCs, and restrained oxidative stress and cell apoptosis in arterial tissues of AS mice. EZH2 regulated miR-139-5p through H3K27me3, and miR-139-5p targeted STAT1. miR-139-5p silencing antagonized the effects of EZH2 down-regulation on AS. This study manifests that down-regulated EZH2 or elevated miR-139-5p inhibits ox-LDL-induced HASMCs apoptosis, plaque formation, and inflammatory response in AS mice, which may be related to down-regulated STAT1.

Alcohol consumption patterns across Europe and adherence to the European guidelines in coronary patients: findings from the ESC-EORP EUROASPIRE V survey

Abstract Introduction Alcohol consumption is an important risk factor for cardiovascular morbidity and mortality worldwide. The highest levels of alcohol consumption are observed in Europe, where alcohol as contributing cause of coronary heart disease (CHD) is also most significant. Purpose To describe patterns of alcohol consumption across different European regions and adherence to the current drinking guidelines in coronary patients with a recent CHD. Methods The EUROASPIRE V survey has been conducted in 2016–2017 at 131 centers in 27 European countries in 9,018 patients with a recent CHD. Median alcohol consumption, as well as the proportions abstainers and excessive drinkers (i.e. >70 grams of alcohol per week for women and >140 grams per week for men, as recommended by the European guidelines on cardiovascular prevention), were calculated for each European region (Eastern, Southern, Northern and Western Europe). To assess adherence to guidelines, proportions of participants who were advised to reduce excessive alcohol consumption, as well as the participants who were incorrectly not advised were calculated per European region. Results Mean age was 64 years (sd=9.5), 75% was male. Abstention rates were 51% in males and 74% in females, whereas excessive drinking was reported by 10% of the males (highest in Western Europe (18%) and lowest in Eastern Europe (5%)) and 6% of the females (also highest in Western Europe (12%) and lowest in Eastern Europe (1.4%)). Overall, 57% of the participants were advised to reduce alcohol consumption. In the total population, 3% was incorrectly not advised (Figure 1), but this percentage differed by region with 9% in Western Europe as compared to 1% in Eastern Europe. In regions where alcohol consumption was highest, participants were less often advised to reduce their consumption. Conclusion In this EUROASPIRE V survey the majority of patients with a recent CHD adhere to the current drinking guidelines and only a fraction of the population was incorrectly not advised to reduce consumption. However, substantial heterogeneity exists between European regions. Figure 1. Distribution of advice given per region Funding Acknowledgement Type of funding source: None

Regulatory Roles of Related Long Non-coding RNAs in the Process of Atherosclerosis.

Atherosclerosis (AS) is the main cause of coronary heart disease, cerebral infarction, and peripheral vascular disease, which comprise serious hazards to human health. Atherosclerosis is characterized by the deposition of lipids on the interior walls of blood vessels, causing an inflammatory response of immune cells, endothelial cells, and smooth muscle cells, and a proliferation cascade reaction. Despite years of research, the underlying pathogenesis of AS is not fully defined. Recent advances in our understanding of the molecular mechanisms by which non-coding RNA influences the initiation and progression of AS have shown that long non-coding RNAs (lncRNAs) regulate important stages in the atherosclerotic process. In this review, we summarize current knowledge of lncRNAs, which influence the development of AS. We review the regulatory processes of lncRNAs on core stages of atherosclerotic progression, including lipid metabolism, inflammation, vascular cell proliferation, apoptosis, adhesion and migration, and angiogenesis. A growing body of evidence suggests that lncRNAs have great potential as new therapeutic targets for the treatment of vascular diseases.

Comparative Analysis of Some Structural Equation Model Estimation Methods with Application to Coronary Heart Disease Risk

This study compared a ridge maximum likelihood estimator to Yuan and Chan (2008) ridge maximum likelihood, maximum likelihood, unweighted least squares, generalized least squares, and asymptotic distribution-free estimators in fitting six models that show relationships in some noncommunicable diseases. Uncontrolled hypertension has been shown to be a leading cause of coronary heart disease, kidney dysfunction, and other negative health outcomes. It poses equal danger when asymptomatic and undetected. Research has also shown that it tends to coexist with diabetes mellitus (DM), with the presence of DM doubling the risk of hypertension. The study assessed the effect of obesity, type II diabetes, and hypertension on coronary risk and also the existence of converse relationship with structural equation modelling (SEM). The results showed that the two ridge estimators did better than other estimators. Nonconvergence occurred for most of the models for asymptotic distribution-free estimator and unweighted least squares estimator whilst generalized least squares estimator had one nonconvergence of results. Other estimators provided competing outputs, but unweighted least squares estimator reported unreliable parameter estimates such as large chi-square test statistic and root mean square error of approximation for Model 3. The maximum likelihood family of estimators did better than others like asymptotic distribution-free estimator in terms of overall model fit and parameter estimation. Also, the study found that increase in obesity could result in a significant increase in both hypertension and coronary risk. Diastolic blood pressure and diabetes have significant converse effects on each other. This implies those who are hypertensive can develop diabetes and vice versa.

Koroner kalp hastalarında paraoksonaz, arilesteraz, lipoprotein (a) ve diğer lipit parametreleri arasındaki ilişki

Objective: Millions of people die every year in industrialized countries due to coronary heart disease (CHD) and rank first among the causes of mortality. It is vital to know the causes of CHD and to determine early diagnosis methods. Low antioxidant enzyme paraoxonase (PONl) activity in High Density Lipoprotein (HDL) structure, which prevents Low Density Lipoprotein (LDL) oxidation, is a risk factor for CHD. Method: For this purpose, serum PONl activities, ARE activities, Lp (a), apo A, apo B and other lipid parameters were investigated in 80 patients who were diagnosed with CHD who applied to the Cardiology Clinic of Firat University Medical Faculty Hospital. CHD group; It consists of coronary heart patients who have undergone myocardial infarction to the cardiology outpatient clinic, or who have decided to by-pass operation as a result of coronary angiography, who use antiischemic drugs, have no diabetes, do not drink alcohol and smoke, do not have coronary heart disease in the family history, do not take lipid-lowering drugs. The control group consists of 40 healthy individuals without cardiovascular disease, diabetes or a disease affecting serum lipid level. Results: Cholesterol, triglyceride (TG), HDL, LDL, VLDL, serum PONl and ARE activities, Lp (a), apo A and apo B levels were found statistically significant in the CHD compared to the healthy control group (p <0.05). Serum PONl activity and ARE activity were lower in the patient groups compared to the healthy control group, and serum Lp (a) levels were higher (p <0.05). Conclusions: Serum PONI activity serum Lp (a) levels, which are accepted as important parameters in the diagnosis of CHD, were also found to be significant biochemical markers in our study.

Alcohol consumption patterns across Europe and adherence to the European guidelines in coronary patients: Findings from the ESC-EORP EUROASPIRE V survey

Background and aimsAlcohol consumption is an important risk factor for cardiovascular morbidity and mortality worldwide. The highest levels of alcohol consumption are observed in Europe, where alcohol as contributing cause of coronary heart disease (CHD) is also most significant. We aimed to describe alcohol consumption patterns across European regions and adherence to the current guidelines in patients with a recent CHD event. MethodsThe ESC-EORP survey (EUROASPIRE V) has been conducted in 2016–2017 at 131 centers in 27 European countries in 7350 patients with a recent CHD. Median alcohol consumption, as well as the proportion of abstainers and excessive drinkers (i.e. >70 g/week for women and >140 for men, as recommended by the European guidelines on cardiovascular prevention), was calculated for each region. To assess adherence to guidelines, proportions of participants who were advised to reduce excessive alcohol consumption and participants who were incorrectly not advised were calculated per region. ResultsMean age was 64 years (SD: 9.5), 75% were male. Abstention rates were 53% in males and 77% in females, whereas excessive drinking was reported by 9% and 5% of them, respectively. Overall, 57% of the participants were advised to reduce alcohol consumption. In the total population, 3% were incorrectly not advised, however, this percentage differed per region (range: 1%–9%). In regions where alcohol consumption was highest, participants were less often advised to reduce their consumption. ConclusionIn this EUROASPIRE V survey, the majority of CHD patients adhere to the current drinking guidelines, but substantial heterogeneity exists between European regions.